KEY — KeyCorp

The Q3 2026 beat and raised guidance support a constructive fundamental narrative—NII grew ~9.6% YoY, credit provisions fell 43%, and analysts are mostly Buy with targets around $23–$25. But as of 2026-10-20 the stock was still down 12.1% over three months and 6.4% below its 200-day SMA, so market price action does not fully confirm the improved story.

The three-year trend is an inflection rather than smooth growth. Q3/Q4 2024 were loss quarters (-$0.47 and -$0.28 EPS) with operating margins of -27% and -22%; since Q1 2025, diluted EPS rose from $0.33 to $0.35, $0.41, $0.43, $0.44, $0.44, and $0.51 in Q3 2026. Q3 2026 operating income was $738M (25.7% margin) versus -$506M in Q3 2024, and net income reached $579M. Revenue data is noisy—FMP shows Q3 2026 revenue of $2.877B while the brief cites $2.05B, and Q2 2026 shows $2.059B—so the EPS/NII recovery is the cleaner signal. Direction: improving, with Q3 2026 the strongest print.

Trailing P/E is 15.5x versus a 5-year average of 11.84x, which looks rich, but the $1.461 TTM EPS does not reconcile with the last four quarterly EPS ($1.82), so the trailing multiple is suspect. On next-FY EPS of $1.835, the forward P/E is ~11.2x—roughly in line with the 11.84x historical average and below the ~13.7x implied by the $25.13 consensus target. P/S is 2.26x versus 2.03x history (slightly rich); P/B is unusable because 2026-09-30 stockholders' equity is shown as -$39M. Net: fair-to-modestly cheap on normalized forward earnings, not cheap on trailing book/sales.

At $20.465 as of 2026-10-20, the stock trades at only ~11.2x next-FY EPS of $1.835; annualizing Q3 2026's $0.51 EPS gets ~$2.04 and ~10x. That suggests the market is not paying for a full recovery—if NII guidance and capital-markets fees hold, earnings could support a mid-$20s price. But the weak 3-month tape says investors want proof on credit and NII durability before closing that gap.

As of 2026-10-20, RSI(14) was 44.56—neutral, not oversold. The $20.47 price was +0.43% vs the 20-day SMA (~$20.4), but -4.69% vs the 50-day (~$21.5) and -6.37% vs the 200-day (~$21.9). With 3-month and 6-month returns of -12.1% and -8.7%, the stock is range-bound below key trend lines. No confirmed reversal yet; reclaiming the $21.5–$22 area would improve entry timing.

• Fed rate path and yield curve: NIM expansion depends on deposit repricing; aggressive rate cuts could pressure NII.
• Regional-bank funding and deposit competition: deposit betas and liquidity costs remain key swing factors.
• Commercial real estate and credit quality: CRE refinancing stress could force higher provisions, reversing the Q3 improvement.
• Regulatory capital and Basel III endgame: capital rules affect buyback capacity and ROTCE targets.
• Capital-markets activity: investment-banking and debt-underwriting fees are sensitive to volatility, rates, and deal flow.

• Q4 2026 earnings on 2027-01-20 and 2027 guidance, especially NII/NIM trajectory.
• Sustained NII growth toward management's ~10% target and NIM near 3%.
• Further recovery in investment-banking and debt-underwriting fees after Q3's 27% sequential jump.
• Progress toward ROTCE >15% through 2027, plus potential buybacks/capital return.
• Clarification of the 2026-09-30 negative stockholders' equity line—likely a data artifact, but a real overhang until resolved.

• The 2026-09-30 balance sheet shows -$39M stockholders' equity versus $19.8B at 2026-06-30; if real, it would be a severe capital/solvency issue, though the move is almost certainly a data or accounting artifact.
• CRE concentration and credit deterioration could reverse the 43% YoY decline in provisions.
• Rate cuts and deposit competition could compress NIM and cause NII guidance to miss.
• Basel III endgame or stress-capital requirements could constrain capital returns.
• Revenue and EPS data inconsistencies (Q2 2026 operating loss with positive net income; TTM EPS mismatch) reduce confidence in reported trends.

KeyCorp is a credible recovery story—EPS has climbed from $0.33 in Q1 2025 to $0.51 in Q3 2026, NII is growing, credit provisions are falling, and the stock trades ~11x forward EPS with a 3.9% dividend. But the negative-equity balance-sheet line and weak technicals mean this is a cautiously constructive setup, not a clean all-clear.

Applied 12.5x to next-FY EPS of $1.835—a modest premium to the 5-year average P/E of 11.84x justified by 8–10% NII growth, the >15% ROTCE target, and stabilizing credit—yielding $22.94.